Study Phase 4

Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population

  • PDF icon for CSR Summary CSR Summary Not Yet Available
  • Globe symbol for NCT Number NCT02385058
  • Notebook for Primary Citation Primary Citation Not Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameMebendazoleProduct NameVERMOXTherapeutic AreaAntiparasitic Products, Insecticides, and RepellentsProduct ClassAnthelminticsPharmacological SubgroupAntinematodal AgentsChemical SubgroupBenzimidazole DerivativesCondition StudiedHelminth Infections
Sponsor Protocol NumberMEBENDAZOLGAI3001Enrollment100Data PartnerJohnson & Johnson% FemaleN/AMean/Median Age (Years)N/A% WhiteN/A

Supporting Documentation

  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the full clinical study report is available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.